- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.05. | ASCO: Innate claims long-term lymphoma data show 'sustained effect' of anti-KIR3DL2 antibody | ||
| 22.05. | ASCO: Cullinan, Taiho unveil lung cancer data behind FDA application plans | ||
| 22.05. | Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs | ||
| 22.05. | Eikon blames US funding cuts for 15% staff reduction centered on research tools business | ||
| 22.05. | Sanofi inks $470M Vigil Neuroscience buyout, brushing off rivals' failures to join Novartis in Alzheimer's race | ||
| 21.05. | France invests €1.3M into novel mRNA project led by OSE Immunotherapeutics | ||
| 21.05. | Merck KGaA shares data justifying pushing lupus drug into phase 3-despite recent setback | ||
| 21.05. | Moderna withdraws FDA filing for flu/COVID combination vaccine, plans resubmission with efficacy data | ||
| 21.05. | Roche's Genentech sticks with Orionis in 2nd molecular glue deal worth $2B | ||
| 21.05. | Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoints in Chinese biotech's first phase 2 win | ||
| 20.05. | PureTech shows durability of pulmonary fibrosis candidate deupirfenidone | ||
| 20.05. | Schrödinger lays off 60 staffers amid 'uncertain times and challenging economic conditions' | ||
| 20.05. | BioNTech pledges £1B to bolster UK presence while nabbing £129M grant from government | ||
| 20.05. | Blueprint changes up $1.67B VantAI pact again, zeroing in on molecular glue potential | ||
| 20.05. | SV Health's latest pharma-backed dementia fund raises $269M to invest in new therapies | ||
| 20.05. | RegenXBio cashes in $250M worth of payments for Zolgensma, 2 other gene therapies | ||
| 20.05. | Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck | ||
| 20.05. | Stars align for CRISPR Tx, Sirius as pair pen siRNA collab with a focus on thrombotic disease | ||
| 19.05. | Prime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off staff | ||
| 19.05. | Atsena eye disease gene therapy hits safety goals, closes retinal splits in phase 1/2 | ||
| 19.05. | Pfizer-backed CellCentric secures $120M for further myeloma trials | ||
| 19.05. | 'Not game-changing': Boehringer's phase 3 lung data get muted response from analysts | ||
| 19.05. | Armata links bacteria-killing virus to clinical responses in phase 2 trial | ||
| 19.05. | Applied's rare disease drug suffers another phase 3 failure months after FDA rejection | ||
| 16.05. | ASGCT: Neurogene details new safety measures after young patient's death in AAV gene therapy trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .